The Investor
07 Apr 2026, 15:34
Sanofi S.A. announced positive Phase 2 results for its experimental drug lunsekimig in respiratory diseases, meeting primary and key secondary endpoints in studies on asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
The AIRCULES study showed significant reductions in asthma exacerbations and improvements in lung function, while the DUET study demonstrated meaningful improvements in nasal polyp scores and patient symptoms. The drug was generally well tolerated across trials.
However, a separate Phase 2 study in atopic dermatitis did not meet its primary endpoint, although some secondary measures showed improvement.
Sanofi said the results support lunsekimig’s potential as a novel treatment targeting multiple inflammatory pathways, with further development ongoing in late-stage trials.
The AIRCULES study showed significant reductions in asthma exacerbations and improvements in lung function, while the DUET study demonstrated meaningful improvements in nasal polyp scores and patient symptoms. The drug was generally well tolerated across trials.
However, a separate Phase 2 study in atopic dermatitis did not meet its primary endpoint, although some secondary measures showed improvement.
Sanofi said the results support lunsekimig’s potential as a novel treatment targeting multiple inflammatory pathways, with further development ongoing in late-stage trials.
